Aizen Therapeutics Unveils AI-Driven ‘Mirror Peptide’ Platform to Revolutionize Drug Development

Aizen Therapeutics Emerges:
Aizen Therapeutics, a Caltech spinout, has debuted with $13 million in seed funding to advance "mirror peptide" drug candidates[1][3].

AI-Driven Platform:
The company uses an AI-driven platform developed by Caltech Professor David Van Valen, MD, PhD, and Aizen's research team to design mirror peptides[3].

Mirror Peptide Benefits:
Mirror peptides have a smaller footprint, allowing them to penetrate solid tumors more effectively before delivering radioactive payloads[1].

Initial Focus:
Aizen's initial focus is on cancer treatment, leveraging the unique properties of mirror peptides to improve drug delivery and efficacy[1].

Funding and Support:
The company has secured $13 million in venture capital from investors, including Madrona, to support its mission to create a new category of biologic medicine[5].